Stay updated with breaking news from Patrick Roth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LAUSANNE, Switzerland, May 17, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a privately-owned,...
Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage repair (DDR) and reverse the poor prognosis for patients with GBM. This multicenter clinical trial launched in the US, Spain and Switzerland is following the preclinical GBM data presented at the annual American Association for Cancer Research 2023 meeting (AACR 2023: Abstract #6185) in Orlando, Florida. L...
Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%.Debiopharm is combining its potent, brain penetrant
WENY News is the ABC, CBS & CW affiliate serving the Twin Tiers region of New York and Pennsylvania.
WENY News is the ABC, CBS & CW affiliate serving the Twin Tiers region of New York and Pennsylvania.